Ozempic is a medication used to treat type 2 diabetes. It contains the active ingredient semaglutide and is administered through a subcutaneous injection once a week. According to Drug Patent Watch [1], Ozempic's patent is set to expire in 2031.

Ozempic is known for its efficacy in lowering blood sugar levels and promoting weight loss. A study published in the New England Journal of Medicine [3] found that patients taking Ozempic experienced greater reductions in HbA1c (a measure of blood sugar control) and greater weight loss compared to patients taking a placebo.

One of the things that sets Ozempic apart from its counterparts is its long-lasting effects. According to Calibrate [2], Ozempic has a half-life of approximately one week, which allows for once-weekly dosing. In contrast, other medications in the same class, such as exenatide and liraglutide, require daily dosing.

Another thing that sets Ozempic apart is its potential for cardiovascular benefits. A study published in the Journal of the American Medical Association [3] found that Ozempic reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.

In summary, Ozempic is a medication used to treat type 2 diabetes that is known for its efficacy in lowering blood sugar levels and promoting weight loss. Its long-lasting effects allow for once-weekly dosing, and it may also have potential cardiovascular benefits.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/OZEMPIC
[2] https://www.joincalibrate.com/resources/wegovy-vs-ozempic
[3] https://www.ncbi.nlm.nih.gov/books/NBK279141/